|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Thomas K. Equels Esq., J.D., M.S.||Exec. Vice Chairman, CEO & Pres||1,24M||N/D||1953|
|Mr. Robert Dickey IV, M.B.A.||Chief Financial Officer||60,98k||N/D||1956|
|Mr. Peter W. Rodino III, Esq., J.D.||COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.||630k||N/D||1951|
|Dr. David R. Strayer M.D.||Chief Scientific Officer & Medical Director||N/D||N/D||1946|
|Ann Marie E. Coverly||Director of Admin. & HR and Deputy Investor Relations Coordinator||N/D||N/D||N/D|
|Dr. Carol A. Smith||Chief Manufacturing Officer & Deputy Chief Scientific Officer||N/D||N/D||1951|
|Dr. Christopher McAleer Ph.D.||Scientific Officer||N/D||N/D||N/D|
|Dr. Ralph Christopher Cavalli Ph.D.||VP of QC & Manufacturing||N/D||N/D||1958|
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
L'ISS Governance QualityScore di AIM ImmunoTech Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.